Status of new anticoagulant drugs.
| Target . | Drug . | Route . | Status . | Indication . |
|---|---|---|---|---|
| VIIa/TF | TFPI* | Intravenous | Phase III | Sepsis |
| NAPc2* | Subcutaneous | Phase II | Thromboprophylaxis in patients undergoing elective knee arthroplasty | |
| Va/VIIIa | APC* | Intravenous | Phase III | Sepsis |
| Xa | Pentasaccharide | Subcutaneous | Phase III | Thromboprophylaxis in patients undergoing elective hip or knee arthroplasty; treatment of venous thrombosis |
| DX-9065a | Intravenous | Phase II | Unstable angina | |
| Xa/IIa | SNAC/heparin* | Oral | Phase II | Thromboprophylaxis in patients undergoing elective hip or knee arthroplasty |
| IIa | Hirudin | Intravenous | Approved | Heparin-induced thrombocytopenia |
| Under review | Unstable angina and non-ST-elevation myocardial infarction | |||
| Bivalirudin | Intravenous | Approved | Alternative to heparin in patients undergoing percutaneous coronary interventions | |
| Argatroban | Intravenous | Approved | Heparin-induced thrombocytopenia | |
| H376/95 | Oral | Phase III | Thromboprophylaxis in patients undergoing elective hip or knee arthroplasty; treatment of venous thrombosis | |
| Phase II | Alternative to warfarin in patients with atrial fibrillation | |||
| Abbreviations: APC, activated protein C; NAPc2, nematode anticoagulant peptide c2; SNAC, sodium N-(8[2-hydroxybenzoyl]amino) caprylate; TFPI, tissue factor pathway inhibitor | ||||
| Target . | Drug . | Route . | Status . | Indication . |
|---|---|---|---|---|
| VIIa/TF | TFPI* | Intravenous | Phase III | Sepsis |
| NAPc2* | Subcutaneous | Phase II | Thromboprophylaxis in patients undergoing elective knee arthroplasty | |
| Va/VIIIa | APC* | Intravenous | Phase III | Sepsis |
| Xa | Pentasaccharide | Subcutaneous | Phase III | Thromboprophylaxis in patients undergoing elective hip or knee arthroplasty; treatment of venous thrombosis |
| DX-9065a | Intravenous | Phase II | Unstable angina | |
| Xa/IIa | SNAC/heparin* | Oral | Phase II | Thromboprophylaxis in patients undergoing elective hip or knee arthroplasty |
| IIa | Hirudin | Intravenous | Approved | Heparin-induced thrombocytopenia |
| Under review | Unstable angina and non-ST-elevation myocardial infarction | |||
| Bivalirudin | Intravenous | Approved | Alternative to heparin in patients undergoing percutaneous coronary interventions | |
| Argatroban | Intravenous | Approved | Heparin-induced thrombocytopenia | |
| H376/95 | Oral | Phase III | Thromboprophylaxis in patients undergoing elective hip or knee arthroplasty; treatment of venous thrombosis | |
| Phase II | Alternative to warfarin in patients with atrial fibrillation | |||
| Abbreviations: APC, activated protein C; NAPc2, nematode anticoagulant peptide c2; SNAC, sodium N-(8[2-hydroxybenzoyl]amino) caprylate; TFPI, tissue factor pathway inhibitor | ||||